| Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.Diabetes Obes Metab | PMID 34463425PMC9292057 | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).Int J Clin Oncol | PMID 34463869无 PMCID | 2021-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.Lancet Respir Med | PMID 34480861PMC8409066 | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).Eur Urol Oncol | PMID 34489210PMC8674146 | 2021-Dec | 0.90 | The study is a randomized Phase III trial of radiotherapy schedules (non-drug intervention) for prostate cancer with a primary quality-of-life endpoint (bowel bother). It does not have a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, RFS, TTP, Kaplan-Meier, HR) as required. | 待处理 |
| Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.Future Oncol | PMID 34521277无 PMCID | 2021-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A multicenter study to evaluate the pharmacokinetics and safety of liposomal bupivacaine for postsurgical analgesia in pediatric patients aged 6 to less than 17 years (PLAY).J Clin Anesth | PMID 34534923无 PMCID | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.Cancer Sci | PMID 34543477PMC8645705 | 2021-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.Am J Psychiatry | PMID 34551584无 PMCID | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial.Mol Cancer Ther | PMID 34552008无 PMCID | 2021-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The cross-sectional association of cognition with diabetic peripheral and autonomic neuropathy-The GRADE study.J Diabetes Complications | PMID 34556408PMC8608739 | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Capacity Building for Primary Stroke Prevention Teams in Children Living With Sickle Cell Anemia in Africa.Pediatr Neurol | PMID 34563875PMC8559257 | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study.Inflamm Res | PMID 34586459PMC8479713 | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.Int J Gynecol Cancer | PMID 34593565PMC8666815 | 2021-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.Clin Genitourin Cancer | PMID 34602349无 PMCID | 2021-Dec | 0.95 | The record meets criteria for oncology, human, randomized, Phase III, and drug intervention, but it is excluded because it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The study reports on pathological response rates and renal function, which are not time-to-event outcomes. | 待处理 |
| Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study.Breast | PMID 34624757PMC8503662 | 2021-Dec | 0.95 | The study is an oncology, human, randomized, Phase 2/3 trial with a drug-containing intervention and reports original results. However, the primary and reported efficacy endpoints are objective response rate (BOR) and disease control rate (DCR), which are categorical outcomes. There is no mention of survival endpoints (OS, PFS, DFS, etc.), Kaplan-Meier survival curves, or hazard ratios in the provided abstract. Therefore, it lacks the required time-to-event efficacy endpoint for inclusion in this KM-digitization cohort. | 待处理 |
| Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.Lancet Gastroenterol Hepatol | PMID 34626550无 PMCID | 2021-Dec | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.Ann Oncol | PMID 34656740无 PMCID | 2021-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.Lancet Respir Med | PMID 34672949PMC8523116 | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 34715071无 PMCID | 2021-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.Leuk Res | PMID 34773794PMC8643322 | 2021-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol | PMID 34793718无 PMCID | 2021-Dec | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.Lancet Neurol | PMID 34800398无 PMCID | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.Lancet Neurol | PMID 34800400无 PMCID | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.Lancet Neurol | PMID 34800417无 PMCID | 2021-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.Nature | PMID 34912120PMC8959470 | 2021-Dec | 0.45 | Primary efficacy endpoint is objective response rate (ORR), not a time-to-event endpoint. Study is eligible otherwise but requires a primary/key secondary time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP, or HR from KM) for inclusion. The time-to-event criterion cannot be established from the provided text. | 待处理 |
| Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.Lancet Healthy Longev | PMID 36098037无 PMCID | 2021-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.Circulation | PMID 34706555PMC8614567 | 2021-Nov-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.Lancet | PMID 34767764无 PMCID | 2021-Nov-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.Blood | PMID 34407542PMC9728405 | 2021-Nov-25 | 0.90 | Eligibility requires a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or KM/HR analysis). This study's primary endpoint is the major molecular response (MMR) rate at week 24, which is a categorical response endpoint, not a time-to-event endpoint. Therefore, it does not meet the inclusion criteria. | 待处理 |
| [Chronic radiation-induced rectal injury after adjuvant radiotherapy for pelvic malignant tumors: report based on a phase 3 randomized clinical trial].Zhonghua Wei Chang Wai Ke Za Zhi | PMID 34823296无 PMCID | 2021-Nov-25 | 0.85 | This is a secondary analysis from a Phase III RCT focusing on quality of life and chronic radiation-induced rectal injury as adverse events, not on survival or progression outcomes relevant to Kaplan-Meier digitization. | 待处理 |
| A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-alpha) vs. Eprex® in patients with anaemia of chronic renal failure.BMC Nephrol | PMID 34823497PMC8620966 | 2021-Nov-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).J Clin Oncol | PMID 34473544PMC8601279 | 2021-Nov-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.J Clin Oncol | PMID 34506246无 PMCID | 2021-Nov-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.J Clin Oncol | PMID 34516759PMC8601309 | 2021-Nov-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.J Clin Oncol | PMID 34538072PMC8601321 | 2021-Nov-20 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial.J Clin Endocrinol Metab | PMID 34228102无 PMCID | 2021-Nov-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.N Engl J Med | PMID 34706189无 PMCID | 2021-Nov-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study.Ocul Immunol Inflamm | PMID 32501774无 PMCID | 2021-Nov-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old.Vaccine | PMID 34706841无 PMCID | 2021-Nov-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study.Gut Liver | PMID 33827990PMC8593495 | 2021-Nov-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Three-year outcomes of the randomized phase III SEIPLUS trial of extensive intraoperative peritoneal lavage for locally advanced gastric cancer.Nat Commun | PMID 34782599PMC8594430 | 2021-Nov-15 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.N Engl J Med | PMID 34534429无 PMCID | 2021-Nov-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.J Clin Oncol | PMID 34406870PMC8577682 | 2021-Nov-10 | 0.95 | Eligible oncology human randomized Phase III trial with time-to-event endpoint, but excluded because the primary randomized intervention (radiation therapy vs. observation) is not drug-containing. Optional tamoxifen use is not the primary drug intervention of the trial. | 待处理 |
| Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.J Clin Oncol | PMID 34436928PMC8577684 | 2021-Nov-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.J Clin Oncol | PMID 34520219无 PMCID | 2021-Nov-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.BMC Public Health | PMID 34749675PMC8576984 | 2021-Nov-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.N Engl J Med | PMID 34551225PMC8482810 | 2021-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer.BMC Cancer | PMID 34736429PMC8569957 | 2021-Nov-04 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials.Rheumatology (Oxford) | PMID 33580248PMC8783538 | 2021-Nov-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).Rheumatology (Oxford) | PMID 33738492PMC8566251 | 2021-Nov-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |